Caladrius Biosciences Announces First Subject Treated in CLBS03 Type 1 Diabetes Phase 2 Trial

Caladrius Biosciences Announces First Subject Treated in CLBS03 Type 1 Diabetes Phase 2 Trial

This post was originally published on this site
Caladrius Biosciences, a cell therapy company combining an industry-leading development and manufacturing services provider with a select therapeutic development pipeline, announces treatment of the first subject in The Sanford Project: T-Rex Study. The T-Rex Study is a Phase 2 trial of Caladrius’ product candidate CLBS03 for the treatment of recent-onset type 1 diabetes in adolescents.

Start the conversation, or Read more at GlobeNewswire.